DOI:
10.1055/s-00032260
Digestive Disease Interventions
LinksClose Window
References
Andtbacka RHI. et al.
OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
J Clin Oncol 2013;
31 (18) LBA9008
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.